Clinical outcomes of bioresorbable versus durable polymer-coated everolimus-eluting stents in real-world complex patients

Marco G Mennuni, Giulio G Stefanini, Paolo A Pagnotta, Elton Pllaha, Marco Araco, Omar A. Meelu, Federica Turati, Bernhard Reimers, Gennaro Sardella, Patrizia Presbitero

Research output: Contribution to journalArticle

Abstract

AIMS: The aim of this study was to evaluate the safety and efficacy profile of new-generation, SYNERGY everolimus-eluting stents (S-EES) as compared to XIENCE everolimus-eluting stents (X-EES) with a durable polymer coating in "complex patients".

METHODS AND RESULTS: We included 2,001 consecutive patients treated with S-EES (n=400) or X-EES (n=1,601) at two Italian centres between May 2013 and May 2015. We used propensity score matching to obtain two cohorts of patients with similar baseline risk profiles. Patients were stratified according to baseline complexity based on the EVOLVE II trial exclusion criteria. The primary outcome was major adverse cardiac events (MACE), defined as the composite of all-cause death, myocardial infarction (MI), and target lesion revascularisation (TLR), at one year. Among 391 matched pairs of patients treated with S-EES or X-EES, we identified 253 (63%) as complex. At one-year follow-up, among "complex" patients, MACE rates did not differ between the S-EES and X-EES groups (9.9% vs. 9.5%, p=0.830, HR 1.04, CI: 0.72-1.48). Similarly, death, MI, and TLR, stratified for complexity, were comparable between S-EES and X-EES treated patients at one year. Of note, no definite ST was observed in either the S-EES or the X-EES cohort.

CONCLUSIONS: New-generation S-EES with a bioresorbable polymer coating appear to be safe and effective irrespective of patient complexity as compared to X-EES.

Original languageEnglish
Pages (from-to)1978-1986
Number of pages9
JournalEuroIntervention
Volume12
Issue number16
DOIs
Publication statusPublished - Mar 20 2017

Keywords

  • Journal Article

Fingerprint Dive into the research topics of 'Clinical outcomes of bioresorbable versus durable polymer-coated everolimus-eluting stents in real-world complex patients'. Together they form a unique fingerprint.

  • Cite this